KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zimmer Biomet Holdings (ZBH) Gains from Sales and Divestitures (2012 - 2025)

Zimmer Biomet Holdings' quarterly Gains from Sales and Divestitures came in at $683000.0 in Q4 2025, up 68.64% year-on-year from $405000.0 in Q4 2024, and up 68.64% quarter-over-quarter from $405000.0 in Q4 2024.

Zimmer Biomet Holdings has reported Gains from Sales and Divestitures for 6 years, with the latest figure at $683000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures rose 68.64% year-over-year to $683000.0; the trailing twelve-month figure through Dec 2025 stood at $683000.0 (up 68.64% YoY), and the FY2025 full-year result was $683000.0, up 68.64% from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 stood at $683000.0, up from $405000.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $683000.0 in Q4 2025, with the low at $168000.0 in Q4 2022.
  • Average Gains from Sales and Divestitures over 4 years is $380250.0, with a median of $335000.0 recorded in 2023.
  • Year-over-year, Gains from Sales and Divestitures soared 52.83% in 2024 and surged 68.64% in 2025.
  • Tracing ZBH's Gains from Sales and Divestitures over 4 years: stood at $168000.0 in 2022, then soared by 57.74% to $265000.0 in 2023, then soared by 52.83% to $405000.0 in 2024, then surged by 68.64% to $683000.0 in 2025.
  • The last three Gains from Sales and Divestitures figures came in at $683000.0 (Q4 2025), $405000.0 (Q4 2024), and $265000.0 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Zimmer Biomet Holdings 16.17 Bn 15.75 Bn 1.51 Bn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 683,000.00
Dec 31, 2025 683,000.00
Dec 31, 2024 405,000.00
Dec 31, 2024 405,000.00
Dec 31, 2023 265,000.00
Dec 31, 2023 265,000.00
Dec 31, 2022 168,000.00
Dec 31, 2022 168,000.00
Dec 31, 2013 434,000.00
Dec 31, 2013 434,000.00
Dec 31, 2012 299,000.00
Dec 31, 2012 299,000.00